SCHEMBL9698322

SCHEMBL9698322

Fc1ccc(Cn2c(NC3CCN(CCNc4ncccn4)CC3)nc3ccncc32)cc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SSTR5 P35346 8/20 0.59
KCNH2 Q12809 8/20 0.56
NR4A2 P43354 2/20 0.56
EED O75530 2/20 0.54
HRH1 P35367 2/20 0.54
HRH4 Q9H3N8 2/20 0.54
LMNA P02545 2/20 0.54
GAA P10253 2/20 0.54
MEN1 O00255 1/20 0.54
MLNR O43193 1/20 0.54
CACNA1F O60840 1/20 0.54
USP2 O75604 1/20 0.54
ABCB11 O95342 1/20 0.54
EGFR P00533 1/20 0.54
HLA-A P04439 1/20 0.54
ERBB2 P04626 1/20 0.54
TP53 P04637 1/20 0.54
CYP1A2 P05177 1/20 0.54
LCK P06239 1/20 0.54
FYN P06241 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1151797 0.93 SSTR5 (0.59) SSTR5KCNH2NR4A2EEDHRH1
SCHEMBL9697183 0.90 SSTR5 (0.72) SSTR5KCNH2NR4A2EEDHRH1
SCHEMBL9869915 0.87 SSTR5 (0.68) SSTR5KCNH2NR4A2EEDHRH1
SCHEMBL11016273 0.86 SSTR5 (0.67) SSTR5KCNH2NR4A2EEDHRH1
SCHEMBL10551207 0.86 SSTR5 (0.58) SSTR5KCNH2NR4A2EEDHRH1
SCHEMBL9564985 0.85 SSTR5 (0.51) SSTR5KCNH2NR4A2EEDHRH1
SCHEMBL9629611 0.85 EED (0.68) SSTR5KCNH2NR4A2EEDHRH1
SCHEMBL9697345 0.85 KCNH2 (0.64) SSTR5KCNH2NR4A2EEDHRH1
SCHEMBL9537238 0.84 KCNH2 (0.43) SSTR5KCNH2NR4A2HRH1LMNA
SCHEMBL1152494 0.84 KCNH2 (0.65) SSTR5KCNH2NR4A2EEDHRH1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130289024-A1 COMPOSITIONS AND METHODS FOR TREATMENT OF FILOVIRUS-MEDIATED DISEASES U.S. ARMY MEDICAL RESEARCH AND MATERIEL COMMAND 2013-10-31 US disclosed
US-RE33833-E Intermediates for antihistamines, antiserotonine agents JANSSEN PHARMACEUTICA N.V. (BE) 1992-02-25 US disclosed
US-4820822-A ANTIHISTAMINE, ANTISEROTONINE AGENTS JANSSEN PHARMACEUTICA (BE) 1989-04-11 US disclosed
US-4760074-A Novel-N-(bicyclic heterocyclyl)-4-piperidinamines JANSSEN PHARMACEUTICA N.V. (BE) 1988-07-26 US disclosed
US-4556660-A ANTIALLERGENS JANSSEN PHARMACEUTICA N.V. (BE) 1985-12-03 US disclosed
EP-0099139-A2 Novel N-(bicyclic heterocyclyl)-4-piperidinamines JANSSEN PHARMACEUTICA N.V. (BE) 1984-01-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130289024-A1 COMPOSITIONS AND METHODS FOR TREATMENT OF FILOVIRUS-MEDIATED DISEASES FLNA, FLNB, PIGS SSTR5 4167/4885KCNH2 2148/4885NR4A2 3277/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.